ArticleFrontiers in immunology2017
HLA Class I or Class II and Disease Association: Catch the Difference If You Can.
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- HLA Class II Alleles and Suicidal Behavior: Evidence from a Case-Control Study.International journal of molecular sciences · 2025Article
- Associations between HLA-II variation and antibody specificity are predicted by antigen properties.Genome medicine · 2025Article
- Evidence for Pathogen-Driven Selection Acting onEcology and evolution · 2025Article
- Evidence for immune activation in pathogenesis of the HLA class II associated disease, podoconiosis.Nature communications · 2024Article
- MMPred: a tool to predict peptide mimicry events in MHC class II recognition.Frontiers in genetics · 2024Article
- Eligibility for Human Leukocyte Antigen-Based Therapeutics by Race and Ethnicity.JAMA network open · 2023Article
- Fifty years after the discovery of the association of HLA B27 with ankylosing spondylitis.RMD open · 2023Article
- Review
- The genetic polymorphisms at the promoter region ofMolecular biology research communications · 2023Article
- Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.Frontiers in pharmacology · 2022Review
- Cancer and Autoimmune Diseases: A Tale of Two Immunological Opposites?Frontiers in immunology · 2022Article
- New pharmacotherapy options for noninfectious posterior uveitis.International ophthalmology · 2021Review
- The Impact of the 'Mis-Peptidome' on HLA Class I-Mediated Diseases: Contribution of ERAP1 and ERAP2 and Effects on the Immune Response.International journal of molecular sciences · 2020Review
- Metal-triggered conformational reorientation of a self-peptide bound to a disease-associated HLA-B*27 subtype.The Journal of biological chemistry · 2019Article
- Ankylosing Spondylitis: A Trade Off of HLA-B27, ERAP, and Pathogen Interconnections? Focus on Sardinia.Frontiers in immunology · 2019Article
- Kidney Transplantation: The Challenge of Human Leukocyte Antigen and Its Therapeutic Strategies.Journal of immunology research · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.